Dr. Reddy's Reports ₹2.40 Billion Semaglutide API Impact In Q1 FY27

Market snapshot: Dr. Reddy's Laboratories reported a significant 69% YoY decline in consolidated net profit to ₹443.5 crore for Q1 FY27, heavily impacted by a ₹239.7 crore provision on its semaglutide active pharmaceutical ingredient inventory. Profitability was further compressed due to macro headwinds including escalating shipping freight costs from Middle East conflict and elevated chemical solvent prices.

Data Snapshot

• Consolidated net profit plunged 68.7% YoY to ₹443.5 crore in Q1 FY27 from ₹1,417.8 crore in Q1 FY26.
• Consolidated Q1 FY27 revenue from operations declined 5.5% YoY to ₹8,070.5 crore from ₹8,545.2 crore.
• EBITDA fell 56% YoY to ₹1,009 crore, dragging the EBITDA margin down by 1,420 basis points to 12.5% from 26.7%.

What's Changed

• Operating margins decreased sharply: Q1 FY27 EBITDA margin fell to 12.5% from 26.7% in Q1 FY26 (derived: down 1,420 bps). Without the ₹239.7 crore semaglutide adjustment, margins would have been 15.4%.
• Net profit margins contracted to 5.5% from 16.6% YoY, heavily dragged by the one-off API inventory provisioning.

Key Takeaways

• Profitability hit by a one-off ₹239.7 crore provision on semaglutide API, dragging gross, EBITDA, and PBT margins down by approximately 300 basis points.
• Operating environment pressured by external logistics inflation driven by Middle East tensions and rising prices of chemical solvents.
• Underlying core business remains robust, delivering healthy double-digit expansion across domestic and key international geographies despite lenalidomide transition headwinds.

SAHI Perspective

The steep net profit drop represents a sharp near-term operational shock, yet it outlines a deliberate containment of the semaglutide API quality issue. While the inventory provisioning of ₹239.7 crore and shipping bottlenecks have compressed operating margins, Dr. Reddy's has successfully established its early-mover footprint in GLP-1 therapy with the launch of oral Obeda tablets in India. Patient capital should track the resolution of API quality validation by September and remediation of the Bachupally biologics observations.

Market Implications

The generic pharma segment may experience temporary sentiment-driven cooling due to the margin erosion at Dr. Reddy's. Elevated chemical solvent costs and global logistical bottlenecks remain crucial variables impacting export-heavy Indian pharmaceutical players in the near term.

Trading Signals

Market Bias: Bearish

Near-term outlook remains cautious following a 69% YoY profit drop and sharp EBITDA margin contraction to 12.5%. Long-term recovery hinges on clearing semaglutide API validation batches by late September.

Overweight: Indian Formulation Peers

Underweight: Export-Focused Pharma Exporters

Trigger Factors:

• Sterility and validation test clearance of new semaglutide API batches by September 2026.
• Remediation progress on the 7 US FDA observations issued to the Bachupally biologics facility.

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian GLP-1 weight management and diabetes therapeutic segment is undergoing a seismic pricing shift following semaglutide patent expiries. Dr. Reddy's has positioned itself as an early full-stack player. On May 20, 2026, the company introduced its generic oral semaglutide biosimilar tablets under the brand 'Obeda' at a price ranging from ₹99 to ₹225 per tablet, targeting India's vast type-2 diabetes population.

Key Risks to Watch

• Prolonged delays in resuming commercial supplies of generic semaglutide if new batches fail validation.
• Further inflation of supply chain freight rates due to escalating geopolitical tensions in the Middle East.
• Regulatory overhang from the US FDA Pre-License Inspection at the Bachupally facility.

Recent Developments

In June 2026, Dr. Reddy's secured generic exclusivity and launched Bosutinib 400mg tablets in the US market. In May 2026, the company commercially launched Obeda oral tablets in India in 3 mg, 7 mg, and 14 mg strengths.

Closing Insight

Despite a challenging transitional quarter burdened by semaglutide quality provisions, Dr. Reddy's underlying generic formulation business remains robust. Efficient execution of its complex generic pipeline remains the vital catalyst for a margin recovery.

High Performance Trading with SAHI.